Clinical Trial

Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes

Study acronym: Cilo-Asa
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Patients with type 2 diabetes and cardiovascular risk factors are at increased risk of cardiovascular events. Therefore, a multi-center prospective randomized study will be conducted to compare the efficacy and safety of cilostazol and aspirin for the prevention of major adverse cardiac and cerebrovascular events (MACCE) in high-risk patients with type 2 diabetes.
Trial Details
NCT Number NCT07719894
Lead Sponsor Seoul National University Bundang Hospital
Conditions Type 2 Diabetes Mellitus (T2DM), Atherosclerosis
Enrollment 1,200 participants
Start Date 2026-05-06
Primary Completion 2028-12 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-22